Adva-27a

Adva-27a is a novel small molecule chemotherapy agent developed as a non-ester GEM-difluorinated C-glycoside derivative of podophyllotoxin. It is designed to overcome multidrug resistance in cancer therapy by evading the P-glycoprotein efflux pump, which is responsible for drug resistance in over 50% of all cancer types. By escaping this efflux mechanism, Adva-27a accumulates inside cancer cells and inhibits Topoisomerase II (specifically topoisomerase IIα), an enzyme critical for DNA unwinding and cell proliferation. This dual mechanism allows it to destroy both drug-sensitive and multidrug-resistant cancer cells more effectively than existing agents like etoposide. Preclinical studies have shown that Adva-27a has superior cytotoxic activity against various human cancer cell lines—including breast, pancreatic, small-cell lung, and uterine sarcoma—and exhibits better metabolic stability and pharmacokinetic properties compared to etoposide[1][2][4][9].